Andrew Dickinson Sells 2,500 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew Dickinson sold 2,500 shares of the company’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the transaction, the chief financial officer owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. The trade was a 1.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $122.81 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a fifty-two week low of $85.60 and a fifty-two week high of $124.11. The stock has a market cap of $152.38 billion, a PE ratio of 24.46, a price-to-earnings-growth ratio of 0.84 and a beta of 0.34. The firm’s fifty day simple moving average is $115.22 and its 200-day simple moving average is $110.52.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same period in the prior year, the company posted $2.01 EPS. The business’s revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is 62.95%.

Institutional Investors Weigh In On Gilead Sciences

Several hedge funds have recently modified their holdings of the stock. Fort Washington Investment Advisors Inc. OH boosted its position in shares of Gilead Sciences by 13.1% in the third quarter. Fort Washington Investment Advisors Inc. OH now owns 2,188 shares of the biopharmaceutical company’s stock worth $243,000 after acquiring an additional 254 shares during the last quarter. HM Payson & Co. boosted its position in shares of Gilead Sciences by 16.6% in the third quarter. HM Payson & Co. now owns 7,060 shares of the biopharmaceutical company’s stock worth $784,000 after acquiring an additional 1,003 shares during the last quarter. Ethic Inc. boosted its position in shares of Gilead Sciences by 2.6% in the third quarter. Ethic Inc. now owns 77,016 shares of the biopharmaceutical company’s stock worth $8,549,000 after acquiring an additional 1,923 shares during the last quarter. Three Seasons Wealth LLC acquired a new stake in shares of Gilead Sciences in the third quarter worth approximately $347,000. Finally, Warren Street Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 4.9% in the third quarter. Warren Street Wealth Advisors LLC now owns 1,921 shares of the biopharmaceutical company’s stock worth $213,000 after acquiring an additional 90 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on GILD. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target on the stock in a research note on Friday, July 25th. The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $105.00 to $108.00 and gave the stock a “neutral” rating in a research note on Friday. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a research note on Tuesday, August 19th. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Finally, Rothschild & Co Redburn lifted their target price on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $119.17.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.